NMP review will have limits

A review of the National Medicines Policy (NMP) would most likely be scoped out before it begins and a name change for the policy could be part of the brief, PBAC chair Professor Andrew Wilson has said.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here